Advertisement
Mr. Kazuyuki Matsui, President and CEO of SBI Asset Management, commented,"SBI is very excited to continue our support and deepen our relationship withQuark Pharmaceuticals. We are encouraged by the progress that Quark has madeand we strongly support the Company's clinical trials going forward."
Advertisement
Daniel Zurr, Chief Executive Officer of Quark, commented, "The additionalfunding we are announcing today will allow us to significantly expand ourclinical program. Between our licensee, Pfizer, and Quark, we anticipatehaving Quark drug candidates in five clinical programs by the second half of2008."
Mr. Zurr continued, "We are thrilled to have the continuous endorsementand support of seasoned investors like SBI Asset Management, who bring yearsof proven experience in building technology companies. It is a vote ofconfidence in our RNAi technology platform, intellectual property and abilityto move candidate products into clinical development."
About Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical companyengaged in discovering and developing novel therapeutic RNAi drug candidates.Quark has a fully integrated drug development platform that spans therapeutictarget identification to drug development. Quark's RNAi technology includesnovel siRNA structures and chemistry that the Company believes provide Quarkwith freedom to operate in the siRNA intellectual property arena, as well asthe ability to deliver siRNA locally and systemically to organs including theeye, ear, kidney, lung, spinal cord and bone marrow.
Quark's current clinical pipeline includes AKIi-5, developed by Quark forthe prevention of acute kidney injury (AKI) following major cardiac surgery,currently in Phase I/IIa clinical trials via systemic delivery. Based onpublicly available information, Quark believes this was the first siRNAdelivered systemically in a human clinical trial.
In addition to AKIi-5, Quark's lead compound, RTP801i-14, licensed toPfizer on an exclusive worldwide basis, is completing Phase I/IIa trials forwet age-related macular degeneration (AMD). Quark expects its partner, Pfizer,to continue to progress RTP801i-14 through Phase II clinical trials for thetreatment of AMD and diabetic macular edema (DME).
Quark is headquartered in Fremont, California and operates research anddevelopment facilities in Boulder, Colorado and Ness-Ziona, Israel. Additionalinformation is available at www.quarkpharma.com.Quark Pharmaceuticals, Inc. The Ruth Group Gavin Samuels Stephanie Carrington / Elizabeth Scott (510) 449 6737 (investors) [email protected] (646) 536-7017 / 7014 [email protected] [email protected] Janine McCargo (media) (646) 536-7033 [email protected]
SOURCE Quark Pharmaceuticals, Inc.
